Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are ...

U.S. President Donald Trump signed an executive order this week to lower the cost of prescription drugs in the United States by requiring drug companies to match the lower prices found in other countr ...

Pfizer has said it will shed staff and cut its operating costs by around $ ... It has not provided any indication of the number of job losses. Around $4.2 billion of the correction will result ...

However, since that period, this valuation has once again declined and there have been announcements ... This has seen Pfizer announce repeated job cuts from its US operations since the beginning ...

Kennedy Jr. Pfizer leans on cost cuts to offset falling revenue Pfizer ... said amid fears President Donald Trump's April 2 tariffs announcement could include products made in Europe.

S&P 500 E-Mini futures (ESM25) are down -0.33%, and June Nasdaq 100 E-Mini futures (NQM25) are down -0.49% this morning, pointing to a pause in the recent rally on Wall Street, while investors await ...

Pfizer will continue operating in Lee County after consolidating facilities. The move comes 18 months after Pfizer confirmed ...

U.S. lawmakers on Thursday asked Pfizer Inc for information on alleged comments by a former executive suggesting its research ...

Tourmaline Bio disclosed results for a potential rival to a Novo Nordisk drug. Elsewhere, data emerged for a psychedelic and CRISPR Therapeutics expanded its toolkit.

COVID-19 shots for healthy younger adults and children will no longer be routinely approved under a major new policy shift unveiled Tuesday by the Trump administration.

The HHS issues more details on President Donald Trump's plans to lower U.S. drug prices through most-favored-nation drug ...